Dendritic cells and pluripotency: Unlikely allies in the pursuit of immunotherapy

Regenerative Medicine

Volumn 10, Issue 3, 2015, Pages 275-286

  Fairchild, Paul J ^a   Leishman, Alison ^a   Sachamitr, Patty ^a   Telfer, Caroline ^a   Hackett, Simon ^a   Davies, Timothy J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cancer vaccination; dendritic cells; embryonic stem cells; genome editing; induced pluripotent stem cells; tolerance induction

Indexed keywords

DENDRITIC CELL VACCINE; PATTERN RECOGNITION RECEPTOR; PLACEBO;

ANTIGEN PRESENTING CELL; CELL DIFFERENTIATION; CELL SUBPOPULATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DNA MODIFICATION; DRUG APPROVAL; DRUG EFFICACY; HEMATOPOIETIC STEM CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LANGERHANS CELL; MELANOMA; META ANALYSIS (TOPIC); MONOCYTE; OUTCOME ASSESSMENT; PATIENT SAFETY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; REVIEW; SCALE UP; SURVIVAL TIME; IMMUNOLOGY; PROCEDURES;

DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MONOCYTES; PLURIPOTENT STEM CELLS;

EID: 84929998200     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.15.6     Document Type: Review

References (76)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
2. Evans MJ, Kauffman M. Establishment in culture of pluripotent cells from mouse embryos. Nature 292, 154-156 (1981).
3. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998).
4. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137(5), 1142-1162 (1973).
5. Mali P, Yang L, Esvelt KM et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
6. Hashimoto D, Miller J, Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity 35, 323-335 (2011).
7. Guilliams M, Ginhoux F, Jakubzick C et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol. 14, 571-578 (2014).
8. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 8(12), 935-947 (2008).
9. Merad M, Manz MG, Karsunky H et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat. Immunol. 3(12), 1135-1141 (2002).
10. Jongbloed SL, Kassianos AJ, McDonald KJ et al. Human CD141+(BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207, 1247-1260 (2010).
11. Bachem A, Güttler S, Hartung E et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J. Exp. Med. 207, 1273-1281 (2010).
12. Lu W, Arraes LC, Ferreira WT, Andrieu J-M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10, 1359-1365 (2004).
13. García F, Climent N, Assoumou L et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J. Infect. Dis. 203, 473-478 (2011).
14. Steele JC, Rao A, Marsden JR et al. Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Ther. 18(6), 584-593 (2011).
15. Oshita C, Takikawa M, Kume A et al. Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial. Oncol. Rep. 28(4), 1131-1138 (2012).
16. Van Nuffel AM, Benteyn D, Wilgenhof S et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol. Ther. 20(5), 1063-1074 (2012).
17. Paluka K, Ueno H, Fay J, Banchereau J. Harnessing dendritic cells to generate cancer vaccines. Ann. NY Acad. Sci. 1174, 88-98 (2009).
18. Naranjo-Gomez M, Raich-Regué D, Oñate C et al. Comparative study of clinical grade human tolerogenic dendritic cells. J. Transl. Med. 9, 89 (2011).
19. Leishman AJ, Silk KM, Fairchild PJ. Pharmacological manipulation of dendritic cells in the pursuit of transplantation tolerance. Curr. Opin. Organ Transplant. 16(4), 372-378 (2011).
20. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 34, 2026-2032 (2011).
21. Creusot RJ, Giannoukakis N, Trucco M, Clare-Salzler MJ, Fathman CG. It's time to bring dendritic cell therapy to Type 1 diabetes. Diabetes 63, 20-30 (2014).
22. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332 (1998).
23. Engell-Noerregaard L, Hansen TH, Andersen MH, Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol. Immunother. 58, 1-14 (2009).
24. Nakai N, Hartmann G, Kishimoto S, Katoh N. Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res. 23, 607-619 (2010).
25. DeFrancesco L. Landmark approval for Dendreon's cancer vaccine. Nat. Biotechnol. 28, 531-532 (2010).
26. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
27. Fairman P, Angel JB. The effect of human immunodeficiency virus-1 on monocyte-derived dendritic cell maturation and function. Clin. Exp. Immunol. 170(1), 101-13 (2012).
28. Fairchild PJ, Brook FA, Gardner RL et al. Directed differentiation of dendritic cells from mouse embryonic stem cells. Curr. Biol. 10(23), 1515-1518 (2000).
29. Senju S, Hirata S, Matsuyoshi H et al. Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. Blood 101, 3501-3508 (2003).
30. Zhan X, Dravid G, Ye Z et al. Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro. Lancet 364, 163-171 (2004).
31. Su Z, Frye C, Bae K-M, Kelley V, Vieweg J. Differentiation of human embryonic stem cells into immunostimulatory dendritic cells under feeder-free culture conditions. Clin. Cancer Res. 14(19), 6207-6217 (2008).
32. Tseng S-Y, Nishimoto KP, Silk KS et al. Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. Regen. Med. 4(4), 513-526 (2009).
33. Senju S, Haruta M, Matsumura K et al. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther. 18(9), 874-883 (2011).
34. Silk KM, Silk JD, Ichiryu N et al. Cross-presentation of tumor antigens by induced pluripotent stem cell-derived CD141+XCR1+ dendritic cells. Gene Ther. 19(10), 1035-1040 (2012).
35. Senju S, Matsunaga Y, Fukushima S et al. Immunotherpay with pluripotent stem cell-derived dendritic cells. Semin. Immunopathol. 33, 603-612 (2011).
36. Kaufman DS. Towards clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 114(17), 3513-3523 (2009).
37. Fairchild PJ, Robertson NJ, Cartland S, Nolan KF, Waldmann H. Cell replacement therapy and the evasion of destructive immunity. Stem Cell Rev. 1(2), 159-167 (2005).
38. Fairchild PJ, Nolan KF, Cartland S, Waldmann H. Embryonic stem cells: a novel source of dendritic cells for clinical applications. Int. Immunopharmacol. 5(1), 13-21 (2005).
39. Senju S, Suemori H, Zembutsu H et al. Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function. Stem Cells 25, 2720-2729 (2007).
40. Choi K-D, Vodyanik MA, Slukvin II. Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors. J. Clin. Invest. 119(9), 2818-2829 (2009).
41. Crozat K, Guiton R, Contreras V et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8α+ dendritic cells. J. Exp. Med. 207, 1283-1292 (2010).
42. Poulin LF, Salio M, Griessinger E et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells. J. Exp. Med. 207, 1261-1271 (2010).
43. Irvine AS, Trinder PKE, Laughton DL et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat. Biotechnol. 18, 1273-1278 (2000).
44. Fairchild PJ, Nolan KF, Graca L, Waldmann H. Stable lines of genetically modified dendritic cells from embryonic stem cells. Transplantation 76, 606-608 (2003).
45. Motomura Y, Senju S, Nakatsura T et al. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res. 66(4), 2414-2422 (2006).
46. Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination. J. Immunol. 172(2), 776-86 (2004).
47. Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405 (2013).
48. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science 346, doi:10.1126/ science.1258096 (2014) (Epub ahead of print).
49. Rughani MG, Gupta A, Middleton MR. New treatment approaches in melanoma: current research and clinical prospects. Ther. Adv. Med. Oncol. 5(1), 73-80 (2013).
50. Blank CU. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr. Opin. Oncol. 26, 204-214 (2014).
51. Loyer V, Fontaine P, Pion S, Hétu F, Roy D-C, Perreault C. The in vivo fate of APCs displaying minor H antigen and/or MHC differences is regulated by CTLs specific for immunodominant class I-Associated epitopes. J. Immunol. 163, 6462-6467 (1999).
52. Tian X, Woll PS, Morris JK, Linehan JL, Kaufman DS. Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. Stem Cells 24(5), 1370-1380 (2006).
53. Fukuma D, Matsuyoshi H, Hirata S et al. Cancer prevention with semi-Allogeneic ES cell-derived dendritic cells. Biochem. Biophys. Res. Commun. 335, 5-13 (2005).
54. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014-1022 (2013).
55. Zeng J, Shahbazi M, Wu C, Toh HC, Wang S. Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression. J. Immunol. 188, 4297-4304 (2012).
56. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J. Immunol. 164, 3095-3101 (2000).
57. Priddle H, Jones DRE, Burridge PW, Patient R. Hematopoiesis from human ES cells: overcoming the immune barrier in stem cell therapies. Stem Cells 24, 815-824 (2006).
58. Kennedy M, Awong G, Sturgeon CM et al. T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures. Cell Rep. 2, 1722-1735 (2012).
59. Sturgeon CM, Ditadi A, Awong A, Kennedy M, Keller G. Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells. Nat. Biotechnol. 32, 554-561 (2014).
60. Encabo A, Solves P, Carbonell-Uberos F, Miñana MD. The functional immaturity of dendritic cells can be relevant to increased tolerance associated with cord blood transplantation. Transfusion 47, 272-279 (2007).
61. Goriely S, Vincart B, Stordeur P et al. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J. Immunol. 166, 2141-2146 (2001).
62. Carreno BM, Becker-Hapak M, Huang A et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J. Clin. Invest. 123(8), 3383-3394 (2013).
63. Goriely S, Van Lint C, Dadkhah R et al. A defect in nucleosome remodelling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J. Exp. Med. 199, 1011-1016 (2004).
64. Yates SF, Paterson AM, Nolan KF et al. Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J. Immunol. 179(2), 967-976 (2007).
65. Vignali DAA, Collison LW, Workman CJ. How regulatory T cell work. Nat. Rev. Immunol. 8, 523-532 (2008).
66. Hirata S, Senju S, Matsuyoshi H, Fukuma D, Uemura Y, Nishimura Y. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cellderived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J. Immunol. 174(4), 1888-1897 (2005).
67. Hirata S, Matsuyoshi H, Fukuma D et al. Involvement of regulatory T cells in the experimental autoimmune encephalomyelitis-preventive effect of dendritic cells expressing myelin oligodendrocyte glycoprotein plus TRAIL. J. Immunol. 178(2), 918-25 (2007).
68. Wang J, Lozier J, Johnson G et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat. Biotechnol. 26, 901-908 (2008).
69. Banugaria SG, Prater SN, Ng YK et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic proteins: lessons learned from infantile Pompe disease. Genet. Med. 13, 729-736 (2011).
70. Messinger YH, Mendelsohn NJ, Rhead W et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet. Med. 14, 135-142 (2012).
71. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132, 661-680 (2008).
72. Schwartz SC, Hubschman J-P, Heilwell G et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379, 713-720 (2012).
73. Schwartz SD, Regillo CD, Lam BL et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet doi:10.1016/S0140-6736(14)61376-3 (2014) (Epub ahead of print).
74. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 11, 268-277 (2011).
75. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19(8), 998-1004 (2013).
76. Asterias biotherapeutics http://asteriasbiotherapeutics.com.